retifanlimab   Click here for help

GtoPdb Ligand ID: 11583

Synonyms: hPD-1 mAb 7(1.2) [6] | INCMGA0012 | MGA012 | retifanlimab-dlwr | Zynyz®
Approved drug Immunopharmacology Ligand
retifanlimab is an approved drug (FDA (2023))
Compound class: Antibody
Comment: Retifanlimab (MGA012) is a humanized IgG4 anti-PD-1 monoclonal antibody. It was developed by MacroGenics for anti-cancer potential. Retifanlimab blocks the interaction between PD-1 and its ligands PD-L1/2, and it acts as an immune checkpoint modulator.
Click here for help
Classification Click here for help
Compound class Antibody
Ligand families/groups Immune checkpoint modulators
Approved drug? Yes (FDA (2023))
International Nonproprietary Names Click here for help
INN number INN
11095 retifanlimab
Synonyms Click here for help
hPD-1 mAb 7(1.2) [6] | INCMGA0012 | MGA012 | retifanlimab-dlwr | Zynyz®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 968
Other databases
GtoPdb PubChem SID 442878617
Search PubMed clinical trials retifanlimab
Search PubMed titles retifanlimab
Search PubMed titles/abstracts retifanlimab